Overview
A group of conditions that are inherited in body and due to which the body is not able to breakdown the long sugar molecules chain called mucopolysaccharides that are found in the human body. This condition is known as mucopolysaccharidoisis. It leads to sugar formation in blood, connective tissues, and cells, which results in various health issues. Mucopolysaccharidosis has about seven forms of conditions. Gernally, majority of affected patients appear to be healthy during birth and witness an interval of common development, and later experience a decrease in their mental and/or physical functioning. With the progress of this condition, it can influence physical abilities, system and organ functioning, appearance, with cognitive development in several cases. The genetic factor underlying may vary in different forms as several cases are inherited in an autosomal recessive way, however a specific form of Type II sticks to inheritance pattern of X-link. Treatment of this condition depends on the symptoms and signs occurring in every patient.
The global mucopolysaccharidosis (MPS) treatment market is expected to manifest a CAGR of 9.8% during the forecast period of 2020-2027 and is expected to have a market valuation of US$ 1,566.5 million in 2020.
Request Here Sample with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/4184
Drivers
Rising approvals of products for improving results of treatment by regulatory authorities is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period.
The focus of major companies contributing in the market on getting their advanced therapeutics approved, is expected to propel growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period. In June 2019, National Medical Products Administration (NMPA) had approved Vimizim (elosulfase alfa) which was developed by Biomarine Pharmaceuticals Inc., for diagnosing the patients with mucopolysaccharidosis type IVA (MPS IVA), called as Morquio A syndrome. In China, Vimizim is the only treatment for this given condition which has been approved.
Major companies adopting various inorganic strategies is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period.
The focus of key companies on adoption of various inorganic strategies such as mergers and acquisitions to reinforce their market positioning in the global mucopolysaccharidosis (MPS) treatment market. In May 2018, an aspect fill and finish services company, Rentschler Fill Solutions and a contract manufacturing organization (CMO), Ultragenyx Pharmaceutical Inc., had partnered to produce an injectable Mepsevii (vestronidase alfa), which a human enzyme beta-glucuronidase in recombinant form, for treatment of patients with a rare genetic disorder condition, MPS VII.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4184
Impact of Coronavirus (Covid-19) Pandemic
The most recent outbreak of SARS-CoV-2 virus was first reported in Wuhan City of China on December 31, 2019. On March 11, 2020, the World Health Organization (WHO) had declared COVID-19 virus as a global pandemic.
As per the World Health Organization’s Coronavirus Disease (COVID-19) Weekly Epidemiological Update, a total of 27 million infections added with 900,000 deaths as a result of COVID-19 were recorded as of September, 2020 worldwide.
COVID-19 pandemic has majorly impacted the economy in three different ways; with its direct effect on manufacture and demand by creating disturbances in the supply chain, with its financial influence on the financial markets and firms. Following the national lockdowns, various countries such as Saudi Arabia, UAE, and Egypt have been facing issues associated with drug transportation among these countries. These factor are expected to hinder growth of the global mucopolysaccharidosis (MPS) treatment market over the forecast period.
Reasons to Purchase this Report
• Current and future of global Mucopolysaccharidosis (MPS) Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Restraints
Poor treatment facilities along with high therapeutics costs are expected to limit growth of the global mucopolysaccharidosis (MPS) treatment market over the forecast period. One of the MPS treatment therapeutics, Vimizin (elosulfase alfa) is used for treatment of Morquio Syndrome (MPS IV) which was expected to cost around US$ 380,000 for yearly diagnosis at the time of its launch in the market. Owing to the high cost associated with it, this treatment cannot be afforded by patients of emerging economies such as India.
Additional hindering factor is the delay related to diagnosing of mucopolysaccharidosis. A study revealed in the Orphanet Journal of Rare Diseases in 2018, there was an occurrence of failure in diagnosing the mucopolysaccharidosis type III and mucopolysaccharidosis type I which are two ultra-orphan diseases.
Key Players
Key companies contributing in the global mucopolysaccharidosis (MPS) treatment market are Bioasis Technologies Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Eloxx Pharmaceuticals, RegenxBio Inc., Takeda Pharmaceutical Company Limited, Sangamo Therapeutics, Inc., Esteve, GC Pharma, JCR Pharmaceuticals Co Ltd., Paradigm Biopharmaceuticals Ltd., Immusoft Corporation, and Inventiva.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Market Dynamics
- Global Mucopolysaccharidosis (MPS) Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
- During-COVID 19 Market Analysis
- Post-COVID 19 Market Analysis
- Key Developments
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Takeda Pharmaceutical Company Limited
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eloxx Pharmaceuticals
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Esteve
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Immusoft Corporation
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Inventiva
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GC Pharma
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegenxBio Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bioasis Technologies Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paradigm Biopharmaceuticals Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837